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Abstract
Background: The Impact of Cancer version 2 (IOCv2) was designed to assess the physical and psychosocial health
experience of cancer survivors through its positive and negative impacts. Although the IOCv2 is available in English
and Dutch, it has not yet been validated for use in French-speaking populations. The current study was undertaken
to provide a comprehensive assessment of the reliability and validity of the French language version of the IOCv2
in a sample of breast cancer survivors.
Methods: An adapted French version of the IOCv2 as well as demographic and medical information were
completed by 243 women to validate the factor structure divergent/divergent validities and reliability. Concurrent
validity was assessed by correlating the IOCv2 scales with measures from the
SF-12, PostTraumatic Growth Inventory and Fear of Cancer Recurrence Inventory.
Results: The French version of the IOCv2 supports the structure of the original version, with four positive impact
dimensions and four negative impact dimensions. This result was suggested by the good fit of the confirmatory
factor analysis and the adequate reliability revealed by Cronbach's alpha coefficients and other psychometric
indices. The concurrent validity analysis revealed patterns of association between IOCv2 scale scores and other
measures.
Unlike the original version, a structure with a Positive Impact domain consisting in the IOCv2 positive dimensions
and a Negative Impact domain consisting in the negative ones has not been clearly evidenced in this study. The
limited practical use of the conditional dimensions Employment Concerns and Relationship Concerns, whether the
patient is partnered or not, did not make possible to provide evidence of validity and reliability of these dimensions
as the subsets of sample to work with were not large enough. The scores of these conditional dimensions have to
be used with full knowledge of the facts of this limitation of the study.
Conclusions: Integrating IOCv2 into studies will contribute to evaluate the psychosocial health experience of the
growing population of cancer survivors, enabling better understanding of the multi-dimensional impact of cancer.
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Background
Patients who have experienced cancer report various con-
cerns related to the physical, psychological, social, and
spiritual domains of their life [1, 2]. Large observational
studies of cancer survivors have reported a range of con-
cerns, even many years after initial treatment, including
fear of recurrence, mood changes and psychological dis-
tress, concerns about body image, sexuality and fertility,
and concerns about finances and employment [3–5]. The
cancer experience can also provide opportunities for per-
sonal growth and strengthened relationships [6, 7].
Cancer-specific quality of life (QOL) instruments (eg:
EORTC QLQ-C30 [8] and FACT-G [9]) were originally
developed to assess the situation of patients during and
shortly after treatment, and primarily in the context of
clinical trials. These questionnaires mainly focused on
acute treatment effects (nausea, fatigue, pain, insomnia)
and the psychosocial effects of being diagnosed with and
treated for cancer in the short term. As patients shift
into the post-primary treatment survivorship phase,
other issues become equally or more salient. For this
reason, a number of questionnaires have been developed
specifically for assessing the physical and psychosocial
health experience of cancer survivors, including the
Quality of Life in Adult Cancer Survivors (QLACS) [10],
the Quality of Life-Cancer Survivors (QOL-CS) [11] and
the Impact Of Cancer (IOC) [12]. Among them, the IOC
questionnaire is the only instrument that focuses on the
positive as well as the negative impacts of the disease on
quality of life that long-term survivors attribute to their
cancer experience.
The Impact of Cancer version 2 (IOCv2) [13] is the 47-
item refined version of the IOC instrument [12]. It is orga-
nized into positive and negative impact dimensions, and
several conditional dimensions applicable to subsets of
survivors (see the Methods section for more details). Posi-
tive impact refers to traumatic event-related personal
growth and includes lifestyle changes such as health be-
haviour, modification of existential values, or changes in
self-evaluation as self-esteem. Negative impact relates to
daily life, changes in employment and relationships, body
changes. It also includes fear of cancer recurrence.
Although the IOCv2 is available in English and
Dutch, it has not yet been validated for use in
French-speaking populations. The current study was
undertaken to provide a comprehensive assessment of
the reliability and validity of the French language ver-
sion of the IOCv2. The need to translate and adapt
the IOCv2 into French also represents an opportunity
to gain better understanding of cross-cultural differ-
ences on feelings associated with the experience of
cancer, and more specifically in the phase after-
treatment, such as the feeling of survivorship, largely
used in Anglo-Saxon populations [14].
Material and methods
The IOCv2 questionnaire
The Impact of Cancer version 2 (IOCv2) is a 47-item
questionnaire organized into 4 positive (altruism and
empathy (AE), health awareness (HA), meaning of cancer
(MOC), positive self-evaluation (PSE)) and 4 negative
(appearance concerns (AC), body change concerns (BCC),
life interference (LI) and worry (W)) impact dimensions
[13] corresponding to the first 37 items. The questionnaire
also includes 10 additional items constituting conditional
dimensions applicable to subsets of survivors assessing
employment concerns (EC), relationship concerns for in-
dividuals with a partner (P), and relationship concerns for
those without a partner (NP). All items are scored on a
five-point scale from 1 = strongly disagree to 5 = strongly
agree. Each dimension score is computed as the mean of
the responses for the items constituting the dimension. A
higher score on a dimension implies stronger endorse-
ment of that content area.
The original validation study of the IOCv2 in breast
cancer survivors yielded high factor loadings (0.58 to
0.94), high internal consistency reliability estimates
(Cronbach’s alpha coefficients between 0.78 and 0.99),
and good discriminatory ability (Ferguson’s delta statistic
values between 0.91 and 0.99). The negative impact di-
mensions scores were positively correlated with the Cen-
ter for Epidemiologic Studies-Depression score. They
were also positively correlated with the Breast Cancer
Prevention Trial Symptom Checklist total score that as-
sesses physical effects of medical interventions to pre-
vent and treat breast cancer.
Translation
The IOCv2 was originally translated into French by a
project group within the European Organisation for Re-
search and Treatment of Cancer (EORTC) Quality of
Life Group using standardized, forward-backward proce-
dures [15]. This first translation of the IOCv2 was ad-
ministered in April-May 2012 to a sample of breast
cancer survivors (n = 371) followed in Gustave Roussy, a
large cancer center in Villejuif, France, but the psycho-
metric analysis of this translation identified two prob-
lematic items. First, the item "I do not take my body for
granted since I had cancer" had been translated to "Je ne
considère plus mon corps comme quelque chose d’ac-
quis depuis le cancer". But the analysis revealed that this
item was weakly correlated with the score of its dimen-
sion Health Awareness and moderately correlated with
the scores of Worry and Body Change Concerns. It was
assumed that the problem lay in the translation of the
idiom "take for granted". With the aim of being consist-
ent with the concept measured through the original di-
mension, the item was reformulated into a statement
exploring the concern about loss of confidence in the
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body: "Depuis le cancer je ne fais plus la même confi-
ance à mon corps”.
Second, the item, "I consider myself to be a cancer sur-
vivor", was initially translated into "Je me considère
comme un survivant du cancer", but this item was
weakly correlated with its initial dimension of Positive
Self-Evaluation in the French version. This item was
then submitted to an internet focus group of after-
cancer patients, thanks to the contribution of a dedi-
cated cancer website, cancercontribution.fr. In French,
surviving evokes mainly a feeling of loss and trauma due
to a catastrophic event, and the word “survivant” in
French is rather empty of pride or honor. As this item is
part of the positive impact domain of IOC, we adopted a
new formulation, "La traversée du cancer m'a rendue
plus forte", to express that the experience of cancer
makes the subject stronger. This formulation avoids fo-
cussing on negative aspects and emphasizes the positive
aspect of having been confronted with cancer.
The first French translation of IOCv2 has thus been
modified by integrating these two adapted items (see
Appendix A). This study examines the psychometric
properties of this second version of the French trans-
lation and adaptation of the IOCv2 in a breast cancer
survivor sample.
Patient sample
Female breast cancer survivors were recruited at Gus-
tave Roussy, a large national comprehensive cancer
centre, where approximately 3000 women are treated
annually for breast cancer. The CANTO project includ-
ing the validation study of the French translation-
adaptation of the IOCv2 was approved by a research
ethics committee (CPP n°11-039, Kremlin Bicetre) in
October 2011. Patients attending their follow-up consult-
ation were approached by a psychologist in April-May
2013. Patients were eligible if they were at least 18 years
old, and were diagnosed with breast cancer more than
1 year earlier. Patients with mental disorders or unable to
fill in the questionnaire without assistance were excluded.
All consecutive eligible patients were invited to participate
in the study. After providing written, informed consent,
the women were asked to complete a series of question-
naires including the IOCv2, the MOS SF-12, the Post-
Traumatic Growth Inventory (PTGI) and the Fear of
Cancer Recurrence Inventory (FCRI). Sociodemographic
and clinical information were also reported by the pa-
tients. Questionnaires were completed in the waiting
room of the outpatient clinic.
Measures
The SF-12 [16, 17] is an abbreviated version of the SF-36.
The information from the 12 items is summarized in phys-
ical (PCS) and emotional (MCS) component summary
scores. Both scores are standardized (mean = 50, SD = 10)
to the 1998 general U.S. population. A higher score indi-
cates a better health. The high correlations between SF-12
and SF-36 summary scores (between 0.94 and 0.96 in
France) support good reproduction of the SF-36 summary
scores by the SF-12 [17]. The Cronbach's alpha coeffi-
cients for the physical (PCS) and emotional (MCS)
component summary scores reach 0.89 showing good
reliability in our sample.
The PostTraumatic Growth Inventory (PTGI) [18]
measures significant positive change with 21 items and
is composed of five dimensions: relating to others, new
possibilities, personal strength, spiritual change and ap-
preciation of life and a total score. All scores result from
the sum of the responses of the corresponding items. A
higher score on a dimension implies a higher change en-
countered in this domain. The Cronbach's alpha coeffi-
cients in our sample for the PTGI dimensions range
from 0.69 to 0.93.
The Fear of Cancer Recurrence Inventory (FCRI) [19]
is a 42-item scale assessing 7 dimensions of the fear of
cancer recurrence (FCR), such as potential triggers acti-
vating FCR, the presence and severity of intrusive
thoughts associated with FCR, psychological distress and
functioning impairments as potential consequences of
FCR, self-criticism towards FCR, and a variety of coping
strategies that can be used to cope with and may influ-
ence FCR. All scores result from the sum of the re-
sponses of the corresponding items. A higher score
indicates increased higher levels of FCR or of other con-
structs associated with the FCR. The validation study of
the FCRI [19] shows good internal consistency and cor-
relations between FCRI and three questionnaires asses-
sing fear of cancer recurrence (between 0.68 to 0.78)
and between FCRI and two questionnaires assessing psy-
chological distress (between 0.43 to 0.66) support con-
struct validity. The Cronbach's alpha coefficients in our
sample for the FCRI dimensions range from 0.71 to 0.95.
Statistical analysis
Confirmatory factor analysis (CFA) based on the original
IOCv2 [13] 8-factor solution (reflecting the 8 hypothe-
sized positive and negative impact dimensions that form
the core of the questionnaire) was performed using
covariance-based structural equation modelling with
maximum likelihood estimation. Good (acceptable) fit
was indicated by the following criteria: RMSEA ≤ 0.05
(0.08), SRMR ≤ 0.05 (0.10), CFI ≥ 0.97 (0.95) and NNFI ≥
0.97 (0.95) [20]. Additional exploratory CFA’s were also
conducted to evaluate the 3 conditional dimensions (em-
ployment and relationship concerns, with or without a
partner) and to explore an higher-order factor structure,
a positive domain consisting of the dimensions Altruism
and Empathy, Health Awareness, Meaning Of Cancer
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and Positive Self-Evalutation and a negative domain con-
sisting of the dimensions Appearance Concerns, Body
Change Concerns, Life Interferences and Worry.
Convergent validity of each dimension was evaluated by
examining the item-rest score correlations between the
items and the rest scores of its hypothesized dimension
(i.e. the score computed from the items of the dimension
deleting that item). The convergent validity of the dimen-
sion was considered good when more than 90 % of the
items of the dimension had an item-rest score correlation
greater than 0.4. This indicates that the items composing
the dimension are likely to be related to the same con-
struct. Divergent validity was evaluated by examining the
item-score correlations between the items and the scores
of the other dimensions. The divergent validity of the di-
mension was considered good when more than 80 % of
the items of the dimension had an item-rest score correl-
ation with its own dimension higher than the item-score
correlations with the other dimensions. This indicates that
the items composing the dimension are not likely to be re-
lated to another construct.
Concurrent validity was evaluated by forming a priori
hypotheses about patterns of association between the
IOCv2 scores and the SF-12, PTGI and FCRI scores. We
expected that the PTGI subscale scores would be corre-
lated with the IOCv2 positive dimensions whereas some
FCRI subscale scores (i. triggers, severity and psycho-
logical distress, and ii. functioning impairments) would
be correlated with the negative ones (i. Worry, and ii.
Body Change Concerns and Life Interference respect-
ively). As the IOCv2 measures a somewhat different
concept than health status, we expected only moderate
associations between IOCv2 scores and SF-12 summary
scores (correlation coefficient’s absolute value between
0.3 and 0.5). The correlation coefficients between dimen-
sions of the IOCv2 were also examined. Positive dimen-
sions (negative dimensions respectively) were expected to
be highly positively correlated with one another.
Internal consistency reliability of the IOCv2 dimen-
sions was assessed using the Cronbach's alpha coefficient
[21]. Dimensions were considered reliable if α > 0.70.
The ability of each dimension to discriminate among in-
dividuals was evaluated with the Ferguson's δ statistic
[22, 23]. Loevinger's H scalability coefficients [24]
evaluate the scalability, i.e. the quality of the scale as
a unidimensional cumulative scale and the degree to
which the set of items is consistent within a dimen-
sion. The scales' and items' Loevinger's coefficients (H
and Hi respectively) were considered acceptable if
H > 0.3 (high degree of homogeneity of the set of
items) and Hi > 0.3 for all i (item consistent with the
set of items). All analyses were performed with Stata
12 (Stata Corp, College Station, Texas). CFA was car-
ried out using LISREL 8.80.
Differences in IOCv2 dimensions as a function of
sociodemographic and treatment characteristics (age,
time since diagnosis, treatment and partner status)
were examined using Pearson correlation coefficients
and Student’s t tests. IOCv2 scores were expected to
vary across treatments, age and time since diagnosis.
These additional elements of validity are to be com-
pared with the results on the original IOCv2 validation
study [13] where the correlation coefficients of the
IOCv2 scores with age were weakly negative. No asso-
ciation was observed between the IOCv2 scores and
time since diagnosis or hormonal therapy. IOCv2
scores were significantly higher for all dimensions for
patients who had received chemotherapy. Finally, Al-
truism and Empathy, Health Awareness and Positive
Self-Evaluation were scored higher for patients with a
partner.
Results
Sample characteristics
In total, 250 women were invited to participate in the
study, of whom 243 (97.2 %) agreed to do so and com-
pleted the questionnaires. Characteristics of the
women are presented in Table 1. The average (standard
deviation) age of the participants was 57.3 (11.3) years.
Three quarters of the sample reported that they were
in a relationship. Most of the subjects had a senior
high school or higher level of education (78 %), and
nearly half were employed during the previous
12 months. Time since diagnosis ranged from 1.1 to
35.7 years, with an average of 5.2 years. Almost all
women had undergone an operation (97 %) and had re-
ceived radiotherapy (95 %). The majority of women
had also undergone adjuvant chemotherapy (69 %) or
hormonal therapy (71 %).
Confirmatory factor analysis
Confirmatory factor analysis of the original 8-factor
structure of the IOCv2 indicated a good fit sug-
gested by most of the criteria (RMSEA = 0.045,
NNFI = 0.97, CFI = 0.97) and an SRMR (=0.084) sug-
gesting acceptable fit. Factor loadings are presented
in Table 2. In addition, a subsample was constructed
for each IOCv2 conditional dimension (i.e., for em-
ployment concerns, relationship concerns for those
with and those without a partner), composed only of
respondents for whom the conditional dimension was
applicable. For each conditional dimension, an add-
itional CFA was performed on each corresponding
subsample, including the items of the conditional di-
mension and the 37 items of the 8 general dimensions
of the IOCv2. These additional CFA’s did not yield
satisfactory results for Employment Concerns and
Partnered dimensions (RMSEA = 0.074, NNFI = 0.91,
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CFI = 0.92, SRMR = 0.11 for Employment Concerns
and RMSEA = 0.069, NNFI = 0.53, CFI = 0.93, SRMR =
0.97 for Partnered). The CFA including the Not Partnered
conditional dimension could not be performed due to the
small number of non-partnered patients.
The higher-order factor structure CFA including
two factors for positive domain and negative do-
main as well as the original 8 factors indicated an
acceptable fit suggested by most of the criteria
(RMSEA = 0.059, NNFI = 0.95, CFI = 0.95) except for
the SRMR (=0.13).
Score description and reliability estimates
The distribution of the scores and the psychometric in-
dices are presented in Table 3. Scores were distributed
along the range of possible values, with Ferguson's δ sta-
tistics ranging from 0.89 to 0.99, indicating good dis-
criminating ability of all the dimensions. All dimensions
but one exhibited acceptable internal consistency with
Cronbach's alpha coefficients ranging from 0.71 to 0.90.
The Altruism and Empathy dimension had a slightly
lower coefficient (α = 0.67). The scale level Loevinger
coefficients varied between 0.37 and 0.69, indicating ac-
ceptable scalability for all dimensions. The Positive im-
pact domain was the only dimension having a scale level
Loevinger coefficient smaller than 0.3 (H = 0.26). All
item level Loevinger coefficients were higher than 0.3,
except for item 22 of the Altruism and Empathy di-
mension ("I feel a special bond with people with
cancer"; Hi = 0.25).
Convergent-divergent and concurrent validity
Convergent validity was evidenced by the high percent-
age of item-rest score correlations higher than 0.4
(94.6 %). Most items (34/37 = 91.9 %) are more
strongly correlated with their own dimension than with
other dimensions, providing good evidence of diver-
gent validity.
Table 4 shows the correlation between the scores of
the IOCv2, the SF-12, the PTGI and the FCRI. The
highest positive correlations within the IOCv2 are
observed amongst the positive impact dimensions
Table 1 Subject characteristics (n = 243)
Age (years), mean ± sd (range) 57.3 ± 11.3 (30–85)
Relationship status, nb (%)
Partnered 183 (76)
Not partnered 58 (24)
Educational status, nb (%)
Elementary school 13 (6)
Junior high school 34 (16)
Senior high school 55 (26)
Higher education level 110 (52)
Employment status, nb (%)
Employed during last 12 months 108 (45)
Not employed 134 (55)
Time since diagnosis (years), mean ± sd (range) 5.2 ± 4.7 (1.1-35.7)
Chemotherapy, nb (%)
Yes 142 (69)
No 64 (31)
Radiotherapy, nb (%)
Yes 218 (95)
No 11 (5)
Surgery, nb (%)
Yes 219 (97)
No 6 (3)
Hormone therapy, nb (%)
Yes 146 (71)
No 60 (29)
Table 2 Factor analysis results according to the original
structure of IOCv2 with four negative impact domains and four
positive impact domains (standardized factor loadings)
Positive impact domains Negative impact domains
Health Awareness Factor loadings Worry Factor loadings
Item 1 0.86 Item 9 0.76
Item 2 0.87 Item 10 0.60
Item 3 0.52 Item 11 0.70
Item 4 0.53 Item 12 0.85
Positive Self-Evaluation Item 13 0.79
Item 5 0.73 Item 14 0.69
Item 6 0.76 Item 15 0.83
Item 7 0.59 Body Change Concerns
Item 8 0.52 Item 16 0.75
Altruism and Empathy Item 17 0.77
Item 22 0.35 Item 18 0.81
Item 23 0.58 Appearance Concerns
Item 24 0.79 Item 19 0.85
Item 25 0.66 Item 20 0.78
Meaning of Cancer Item 21 0.66
Item 33 0.49 Life Interferences
Item 34 0.72 Item 26 0.52
Item 35 0.81 Item 27 0.68
Item 36 0.75 Item 28 0.55
Item 37 0.80 Item 29 0.54
Item 30 0.75
Item 31 0.60
Item 32 0.69
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(Positive impact dimensions Summary score, Altruism
and Empathy, Health Awareness, Meaning of Cancer
and Positive Self-Evaluation) and amongst the negative
impact dimensions (Negative impact dimensions Summary
score, Appearance Concerns, Body Change Concerns, Life
Interference and Worry). The negative impact dimensions
scores are also positively correlated with the conditional
dimensions (Employment Concerns, Not Partnered and
Partnered).
With regard to the correlations with other instru-
ments, the scores of the Altruism and Empathy,
Meaning Of Cancer and Positive Self-Evaluation di-
mensions were positively correlated with all the
PTGI scores. High scores on PTGI scales indicate
more posttraumatic growth, whereas high scores on
IOCv2 positive dimensions reflect more positive im-
pacts of cancer. In contrast, the negative dimensions
Life Interference and Worry of the IOCv2 showed
positive correlations with all the dimensions of the
FCRI except Coping Strategies. High scores on the
FCRI dimensions indicate more concerns about can-
cer recurrence and high scores on the IOCv2 nega-
tive dimensions reflect more negative impacts of
cancer. All the negative dimensions of the IOCv2
(Appearance Concerns, Body Change Concerns, Life
Interference and Worry) were negatively correlated
with the Mental Component Summary score of the
SF-12, and the Body Change Concerns and Life
Interference dimensions of the IOCv2 also correlated
negatively with the Physical Component Summary
score of the SF-12. High scores on the SF12 indicate
better health status, and are associated with lower
levels of negative impacts as assessed by the IOCv2.
Additional elements for validity
The associations observed between the IOCv2 dimen-
sions and sociodemographic and medical variables are
presented in Table 5. The very weak correlations of the
IOCv2 dimensions scores with time since diagnosis
indicate that the impact of the cancer experience,
both positive and negative, did not change signifi-
cantly as a function of time. Age was most strongly
and negatively correlated with The Health Awareness
dimension of the IOCv2. Younger women scored
higher than older women, indicating a greater aware-
ness of health. Respondents who received chemo-
therapy tended to score higher than others on both
positive and negative impact dimensions. In particu-
lar, those women who had undergone chemotherapy
were more likely to report more concerns about ap-
pearance. All these trends are in accordance with
the original IOCv2 validation study [13]. Women
who had undergone radiotherapy tended to have
higher scores on the negative impact dimensions of
the IOCv2 and lower scores on the positive impact
dimensions, especially for the Meaning of Cancer di-
mension, than women who had not undergone
radiotherapy. Women who received hormonal ther-
apy tended to score higher than others on negative
impact dimensions of the IOCv2. No patterns
emerged for women who had surgery probably be-
cause only 6 women (3 %) did not have surgery.
Table 3 Score description of IOCv2 dimensions and psychometric indices
IOCv2 Number of items mean ± sd (range) Cronbach's alpha Ferguson's delta Loevinger's H
Positive impact dimensions
Summary Score 17 3.4 ± 0.6 (1.1-5) 0.83 0.97 0.26
Altruism and Empathy 4 3.7 ± 0.7 (1–5) 0.67 0.89 0.37
Health Awareness 4 3.8 ± 0.8 (1–5) 0.71 0.90 0.41
Meaning Of Cancer 5 2.9 ± 0.9 (1–5) 0.85 0.93 0.58
Positive Self-Evaluation 4 3.3 ± 0.9 (1–5) 0.74 0.92 0.45
Negative impact dimensions
Summary Score 20 2.9 ± 0.8 (1–4.8) 0.92 0.98 0.42
Appearance Concerns 3 2.8 ± 1.2 (1–5) 0.85 0.91 0.69
Body Change Concerns 3 3.1 ± 1.2 (1–5) 0.82 0.92 0.65
Life Interference 7 2.4 ± 0.8 (1–4.7) 0.81 0.95 0.42
Worry 7 3.3 ± 1.0 (1–5) 0.90 0.96 0.62
Employment Concerns 3 2.4 ± 1.0 (1–5) 0.76 0.92 0.56
Relationship Concerns (Not Partnered) 3 2.6 ± 1.0 (1–5) 0.75 0.90 0.45
Relationship Concerns (Partnered) 4 1.8 ± 0.8 (1–5) 0.68 0.85 0.46
Blanchin et al. Health and Quality of Life Outcomes  (2015) 13:110 Page 6 of 12
Patients without partner were more likely to report
relationship concerns when they had not undergone
hormonal therapy than patients without partner that
had undergone hormonal therapy.
Discussion
In this paper, we have reported the results of a study of
the psychometric performance of the French language-
version of the IOCv2 questionnaire. The good fit of the
confirmatory factor analysis suggests that the French ver-
sion supports the 8-factor structure of the original version,
with four positive impact dimensions and four negative
impact dimensions. The Cronbach's alpha coefficients and
other psychometric indices indicate adequate reliability,
and the correlation coefficient values support the validity
of the French version. As expected, we have found nega-
tive correlations between some of the negative dimensions
of the IOCv2 and the Mental and Physical Component
Table 4 Correlation coefficients between SF-12 summary, PTGI, FCRI and IOCv2 scores
Positive impact dimensions Negative impact dimensions
SS AE HA MOC PSE SS AC BCC LI W
Positive impact dimensions
Summary score (SS) 1.00
AE 0.72* 1.00
HA 0.51* 0.38* 1.00
MOC 0.80* 0.39* 0.10 1.00
PSE 0.73* 0.35* 0.12 0.50* 1.00
Negative impact dimensions
Summary score (SS) 0.09 0.29 0.48* −0.16 −0.18 1.00
AC −0.06 0.03 0.22 −0.18 −0.15 0.68* 1.00
BCC 0.06 0.22 0.35* −0.12 −0.16 0.83* 0.61* 1.00
LI 0.14 0.35* 0.37* −0.09 0.09 0.87* 0.49* 0.67* 1.00
W 0.10 0.26 0.51* −0.15 −0.19 0.84* 0.37* 0.55* 0.60* 1.00
EC (N = 106) 0.09 0.25 0.26 −0.04 −0.13 0.45* 0.19 0.31* 0.53* 0.34*
NP (N = 57) −0.13 0.21 0.26 −0.33* −0.16 0.60* 0.49* 0.34* 0.63* 0.51*
P (N = 168) 0.14 0.22 0.17 0.02 0.05 0.42* 0.26 0.18 0.51* 0.32*
SF-12 MCS 0.03 −0.16 −0.20 0.16 0.16 −0.61* −0.36* −0.46* −0.56* −0.53*
SF-12 PCS −0.07 −0.14 −0.12 0.07 −0.06 −0.40* −0.25 −0.55* −0.35* −0.24
PTGI
Relating to others 0.62* 0.51* 0.28 0.53* 0.38* −0.02 −0.07 −0.01 −0.03 0.01
New possibilities 0.64* 0.39* 0.18 0.69* 0.41* −0.10 −0.11 −0.14 −0.03 −0.08
Personal strength 0.63* 0.35* 0.11 0.64* 0.56* −0.18 −0.12 −0.12 −0.16 −0.16
Spiritual change 0.45* 0.35* 0.14 0.41* 0.31* −0.04 −0.06 −0.05 0.02 −0.06
Appreciation of life 0.58* 0.36* 0.32* 0.55* 0.32* 0.02 −0.11 −0.02 0.05 0.06
Total score 0.73* 0.50* 0.26 0.70* 0.49* −0.08 −0.11 −0.08 −0.04 −0.06
FCRI
Triggers 0.17 0.32* 0.37* −0.06 −0.01 0.45* 0.18 0.18 0.36* 0.56*
Severity 0.11 0.28 0.45* −0.16 −0.08 0.64* 0.31* 0.37* 0.47* 0.74*
Psychological distress 0.15 0.31* 0.38* −0.08 −0.06 0.55* 0.28 0.28 0.46* 0.60*
Functioning impairments 0.08 0.27 0.28 −0.09 −0.12 0.66* 0.34* 0.44* 0.64* 0.59*
Insight 0.19 0.28 0.26 0.00 0.06 0.40* 0.15 0.18 0.42* 0.40*
Reassurance 0.20 0.24 0.27 0.05 0.07 0.32* 0.11 0.20 0.26 0.35*
Coping strategies 0.30* 0.33* 0.30* 0.14 0.14 0.20 0.03 0.12 0.14 0.26
Total score 0.23 0.40* 0.47* −0.05 −0.01 0.64* 0.28 0.35* 0.54* 0.70*
* indicates correlation coefficient ≤ −0.30 or correlation coefficient ≥0.30
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scores of the SF12. We also observed positive correlations
between the positive dimensions of the IOCv2 and the
PTGI scores, and between the negative dimensions of
the IOCv2 and the FCRI scores. These results support
the construct validity of the IOCv2, and its ability to cap-
ture a range of positive and negative psychosocial health
experiences with a relatively limited number of items.
Nevertheless, we note weak correlation coefficients be-
tween some positive dimensions, in particular between
HA and MOC (0.10), and HA and PSE (0.12). These re-
sults point out the fact that the four positive dimensions
do not form a consistent set of items. Consequently, the
construct of a summary score by aggregating these four
positive dimensions produces a set of items with a poor
scalability (H = 0.26). This result could explain medium
performance of the hierarchical CFA. A structure with a
Positive Impact domain consisting in the IOCv2 positive
dimensions and a Negative Impact domain consisting in
the negative ones has not been clearly evidenced in this
study.
The limited practical use of the conditional dimen-
sions Employment Concerns and Relationship Con-
cerns, whether the patient is partnered or not, did
not make possible to provide evidence of validity and
reliability of these dimensions as the subsets of sam-
ple to work with were not large enough. The scores
of these conditional dimensions have to be used with
full knowledge of the facts of this limitation of the
study.
A low correlation has been observed between the
item ‘I feel a special bond with people with cancer’ and
the score computed using the other items of its dimen-
sion Altruism and Empathy. This might be explained,
at least in part, by cultural differences in the attitudes
in the way that survivors feel connected (or not) with
the cancer survivor community. In contrast to some
countries, it is our impression that engagement in
community and advocacy movements is low among
French-speaking survivorship population, thus result-
ing in a limited sense of group identity. This result is
in accordance with the results of the comparison be-
tween Dutch and American non-Hodgkin lymphoma
survivors regarding IOC [25] where the IOC question-
naire is said to be culturally sensitive. The paper
pointed out that the cultural differences between USA
and Western Europe in terms of social safety net and
health care systems as well as the well-developed pro-
grams in cancer survivorship care such as social
Table 5 Correlations between IOCv2 dimensions and sociodemographic and treatment characteristics and mean scores of IOCv2
dimensions
Chemotherapy Radiotherapy Surgery Hormonotherapy Partnered
Time
since
diagnosis
Age No Yes No Yes No Yes No Yes No Yes
N = 64 N = 142 N = 11 N = 218 N = 6 N = 219 N = 60 N = 146 N = 58 N = 183
Positive impact dimensions
SS −0.05 −0.13* 3.28 3.43 3.65 3.37 3.42 3.39 3.40 3.42 3.37 3.47
AE 0.01 −0.08 3.56 3.73 3.68 3.68 3.63 3.70 3.72 3.71 3.71 3.68
HA −0.08 −0.17* 3.75 3.86 4.00 3.80 4.00 3.81 3.80 3.88 3.87 3.80
MOC 0.01 −0.02 2.74 2.90 3.45* 2.83* 2.77 2.86 2.89 2.91 2.99 2.84
PSE −0.08 −0.11 3.21 3.38 3.52 3.32 3.50 3.34 3.36 3.32 3.42 3.31
Negative impact dimensions
SS −0.04 −0.04 2.70 2.92 2.66 2.85 3.12 2.85 2.77 2.91 2.85 2.91
AC −0.03 −0.12 2.44* 2.85* 2.73 2.70 2.93 2.71 2.42* 2.82* 2.70 2.78
BCC −0.05 −0.01 2.93 3.18 2.61 3.08 3.17 3.08 2.9 3.18 3.05 3.09
LI −0.01 0.00 2.30 2.47 2.17 2.43 2.71 2.42 2.39 2.47 2.54 2.38
W −0.04 −0.03 3.11 3.31 3.14 3.25 3.54 3.25 3.25 3.29 3.31 3.25
N = 28 N = 73 N = 5 N = 100 N = 3 N = 101 N = 27 N = 71 N = 79 N = 27
EC −0.06 0.07 2.21 2.48 2.27 2.43 2.56 2.42 2.53 2.34 2.40 2.44
N = 11 N = 40 N = 2 N = 53 N = 1 N = 53 N = 10 N = 42
NP −0.14 0.03 2.33 2.75 2.50 2.63 NA NA 3.33* 2.42*
N = 51 N = 95 N = 9 N = 155 N = 4 N = 158 N = 45 N = 103
P 0.13 0.19* 1.77 1.78 1.33* 1.82* 2.38 1.77 1.63 1.85
* p value of the t test < 0.05
NA: not applicable
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support in North America might explain that the con-
cepts of altruism and empathy and the feeling of be-
longing to a group of cancer survivors are more
developed in USA.
It should be mentioned here that reformulation of
items 1 and 5, as explained in the Methods section,
has allowed better convergence between the original
version and its translation. Therefore, we can con-
sider that results drawn from both versions of the
IOCv2 through two language-wise different samples
may be equally reliable and allow transcultural
comparisons.
Sociodemographic characteristics of our sample dif-
fered from those of the original U.S. validation study.
French-speaking breast cancer survivors were younger,
more often employed and more often partnered. These
are characteristics that may contribute to better psy-
chosocial adjustment during the survivorship period.
There were also differences between the two study
samples in disease and treatment-related factors.
French-speaking women responded to the question-
naire less than 5 years after diagnosis, and therefore
they were not considered yet as long-term survivors.
Moreover, a greater percentage of the French-speaking
sample had undergone chemotherapy, treatment asso-
ciated with significant long-term toxicity effects. Yet,
despite these differences in sample composition, the
psychometric performance of the IOCv2 was consist-
ently good.
Our study has several limitations that should be men-
tioned. First, the study was restricted to breast cancer
survivors which implies that further validation work
across different cancer diagnoses is needed to propose
this tool as a widely useful instrument for cancer survi-
vors. Evidence from the U.S. [26, 27] and the Netherlands
[25, 28] suggest that the IOCv2 is also suitable for
use with other diagnostic groups. Second, the study
employed a cross-sectional design. Future longitudinal
studies are needed to investigate the responsiveness of
the IOCv2 to changes over time in the survivorship ex-
perience. This is particularly important, because the
data from our cross-sectional investigation such that
the psychosocial impact of cancer and its treatment
during the post-primary treatment survivorship period
remains relatively stable. Only a longitudinal study
design can provide the evidence needed to determine if
this is in fact the case. Finally, and conversely, well-
designed studies are needed to examine the stability of
the IOCv2; that is, its reproducibility under conditions
of no or limited change.
Our study also had a number of strengths. First,
our psychometric study was based on a thorough and
carefully conducted translation process that ensured
that the French language version of the IOCv2 to be
tested was of high quality. Second, the study sample
was relatively large and has a very high participation
rate, supporting the generalizability of our findings
to the population of French breast cancer survivors.
Finally, we premised much of the analysis (e.g., the
confirmatory factor analysis and the validity testing)
on a priori hypotheses about the structure of the
questionnaire and its association with other mea-
sures and with various sociodemographic and clinical
variables.
The French-language version of the IOCv2 is currently
being used as one of the assessment tools of a recently
created, large cohort of breast cancer survivors in
France, the CANTO cohort. Creation of this cohort,
with 12,000 women with non-metastatic breast cancers,
will facilitate the study of long term physical, psycho-
logical, social, and economic consequences of the pri-
mary breast cancer and its treatment. Importantly, use
of the IOCv2 in this study will bring not only the nega-
tive, but also the positive consequences of having had
breast cancer into focus. The IOCv2 will allow such a
detailed evaluation through a limited number of items.
As the IOCv2 focuses on quality of life impacts attrib-
uted to the cancer experience, it remains recommended
to jointly use other generic HRQOL measures to evalu-
ate other health related quality of life aspects, as applied
in the assessment of the CANTO cohort that integrates
the current validation work. The information gener-
ated by this and future epidemiological and clinical
studies will hopefully contribute to developing optimal
clinical pathways and survivorship care plans for
women with breast cancer.
Conclusion
The IOC questionnaire was originally developed and
validated among a mixed sample of cancer survivors.
The IOCv2 questionnaire, a refined version of the IOC,
was validated among long-term breast cancer survivors
in the United States. The impetus for developing the
questionnaire was an awareness of the need to evaluate
the psychosocial health experience of the growing
population of cancer survivors, enabling better under-
standing of the multi-dimensional impact of cancer.
The French version of the IOCv2 demonstrates good
psychometric properties, and thus is appropriate for
use in studies in France and perhaps in other French-
speaking countries as well (although this latter use
needs to be confirmed).
Results from studies using the IOCv2 may contribute
not only to enhance descriptive research on cancer sur-
vivors’ unmet psychosocial needs, but also to designing
high quality research on the effectiveness of psychosocial
interventions aimed at improving the cancer survivor-
ship experience.
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Appendix A: French version of the IOCv2
questionnaire
Questionnaire sur l’impact du cancer, IOC version 2
Table 6 Instructions: étant donné votre vie actuelle, que ressentez-vous par rapport au fait d’avoir eu un cancer ? Veuillez entourer le
chiffre décrivant le mieux à quel point vous êtes d’accord ou non avec chacun des énoncés
Pas du tout d’accord Pas d’accord Neutre D’accord Tout à fait d’accord
1 2 3 4 5
1. Depuis le cancer je ne fais plus la même confiance à mon corps
2. Je suis plus soucieux(se) de ma santé depuis que j’ai eu un cancer
3. Je suis plus conscient(e) des problèmes physiques ou des
changements de mon corps depuis que j’ai eu un cancer
4. Je prends mieux soin de moi (de ma santé) depuis que j’ai eu
un cancer
5. La traversée du cancer m’a rendu plus forte
6. Je ressens un sentiment de fierté ou d'accomplissement pour
avoir survécu au cancer
7. Avec le cancer, j’ai appris quelque chose sur moi-même
8. J’ai l’impression d’être un modèle pour les autres personnes
atteintes d’un cancer
9. Je doute de mon avenir depuis que j’ai eu un cancer
10. J’ai l’impression qu’il ne me reste plus beaucoup de temps à vivre
11. Je m’inquiète à l’idée que le cancer revienne ou d’avoir un autre cancer
12. Je doute de ma santé depuis que j’ai eu un cancer
13. Je m’inquiète au sujet de mon avenir
14. Lorsque j’ai de nouveaux symptômes (douleurs, tomber malade
ou attraper la grippe), je m'inquiète d’un retour du cancer
15. Je m'inquiète au sujet de ma santé
16. Je suis préoccupé(e) par le fait de ne pas avoir retrouvé l’énergie
que j’avais avant d’avoir un cancer
17. Je suis gêné(e) par le fait que mon corps ne puisse plus faire ce
qu’il faisait avant d’avoir eu le cancer
18. Je me sens vieux/vieille depuis que j’ai eu un cancer
19. Je m’inquiète au sujet de l’apparence de mon corps
20. Je me sens défiguré(e)
21. Je couvre parfois les parties de mon corps que je ne veux pas
que les autres voient
22. J’ai l’impression d’avoir un lien particulier avec les personnes
atteintes d’un cancer
23. Du fait que j’ai eu un cancer, je comprends mieux ce que
peuvent ressentir les autres quand ils sont gravement malades
24. J’ai davantage envie d’aider les autres depuis que j’ai eu le cancer
25. J’ai l’impression que je devrais donner quelque chose en
retour aux autres du fait que j’ai survécu au cancer
26. Je culpabilise aujourd'hui de ne pas avoir été disponible
pour ma famille lorsque j'avais le cancer
27. J’ai l’impression que le cancer dirige ma vie
28. Je me sens seul(e) depuis que j’ai eu un cancer
29. Depuis que j’ai eu un cancer, j’ai l’impression que certaines
personnes (amis, famille, collègues) ne me comprennent pas
30. L’incertitude de mon avenir influence mes décisions de faire
des projets (par exemple: travail, loisirs/voyages, se marier,
s’engager dans une relation, avoir une famille, aller en cours)
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